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In an attempt to find a serological marker for the diagnosis of chronic digestive forms of Chagas' disease, we
compared amastigote and trypomastigote antigens obtained from immunosuppressed mice infected with
Trypanosoma cruzi (Y strain) with conventional epimastigote antigens to search for immunoglobulin A (IgA)
antibodies. A total of 255 serum samples from patients with acute and chronic (indeterminate, digestive, and
cardiac) forms of Chagas' disease and with nonchagasic diseases and from healthy individuals were studied.
Amastigote antigens proved to be the most adequate for our purpose, since IgA antibodies could be detected
in 23 of 25 serum samples from patients with digestive forms, with relative indices of sensitivity, specificity, and
efficiency of 0.920, 0.911, and 0.912, respectively. These antigens also showed high reactivity with IgA
antibodies, with a geometric mean titer of 16,635 (12.7 log2). IgA antibodies were detected in 16 of 28 serum
samples from patients with the acute form as well, but this clinical form is easily distinguished from the chronic
form by the demonstration of IgM antibodies. Poor results were seen with trypomastigote and epimastigote
antigens. The finding of IgA antibodies in about 20% of indeterminate forms and 20% of cardiac forms,
although in low titers, requires further investigation to ascertain their role as an early signal of gastrointestinal
lesions. In addition, the amastigote antigens described here seem more convenient for use in endemic areas than
those obtained from cell cultures because of their lower cost.
In areas in which Chagas' disease is endemic, digestive
forms either associated with or not associated with myocar-
diopathies have been reported to occur in about 7 to 14% of
the chronic cases (7, 17, 18). Radiologic diagnosis is of
limited sensitivity, since it detects severe or moderate but
not earlier phases of gastrointestinal dilatations. For this
purpose, more sensitive methods are therefore required (18).
Present serological tests, although very suitable for the
diagnosis of Trypanosoma cruzi infections, provide no infor-
mation on pathological differences among chronic forms of
the disease (6, 13). In digestive forms, Ferreira et al. (11)
found increased levels of total immunoglobulin A (IgA) in
serum, but specific IgA antibodies could be detected in only
about one-half of the cases by an immunofluorescence (IF)
test with T. cruzi epimastigotes as antigens. Antigenic dif-
ferences have been demonstrated between life cycle stages
of T. cruzi (15). Trypomastigotes have been shown to be
useful for the demonstration of lytic antibodies, which are
considered markers of active infections (16). However, in an
IF test, amastigotes have been found to be more reactive
than other parasite stages (8, 10). We tried to better inves-
tigate IgA antibodies in digestive forms of Chagas' disease
by using an IF test with T. cruzi amastigotes, trypomasti-
gotes, and epimastigotes as antigens.
MATERIALS AND METHODS
Serum samples. Serum samples were collected from 255
individuals, 135 of which had Chagas' disease, 70 of which
had nonrelated infections or autoimmune diseases, and 50 of
which were clinically healthy. Chagasic patients included 28
with acute (group 0), 56 with chronic indeterminate (group
1), 26 with cardiac (group 2), and 25 with digestive (group 3)
* Corresponding author.
forms. All acute infections (group 0) were parasitologically
confirmed by direct microscopic examinations of blood
samples or xenodiagnosis. Of these cases, 7 patients were
from an endemic area (J. C. Pinto Dias, Bambui, Brazil), and
the remaining 21 patients had acquired the disease via a
blood transfusion in the city of Sao Paulo. Chronic cases
were selected by one of us in the Hospital das Clinicas da
Universidade Estadual de Campinas, Campinas, Brazil, and
classified according to clinical, electrocardiographic, and
radiological criteria. Group 1 included patients with no
clinical signs or symptoms of the disease and a normal or
only slightly abnormal electrocardiogram. Group 2 patients
had cardiomyopathy with cardiac insufficiency, cardiomeg-
aly, and an abnormal electrocardiogram. Group 3 included
patients with radiographically detected digestive abnormali-
ties. In 11 of the 25 cases in this group, cardiac disease was
also present.
A total of 70 patients with nonrelated infections were
studied: 10 with clinically active rubella; 10 with acute
toxoplasmosis; 10 with malaria with patent parasitemia; 10
of different age groups and from areas not endemic for
Chagas' disease with clinically active kala-azar; 10 with
mucocutaneous leishmaniasis; 10 with recent syphilis; and
10 with connective tissue diseases, including 5 with antinu-
clear antibodies and 5 with high-titer rheumatoid factors. Of
the clinically healthy individuals, 20 were selected in an area
endemic for Chagas' disease, and 30 were blood bank
donors. Negative serology (complement fixation, IF, and
indirect hemagglutination [HA] tests) for Chagas' disease
was seen in all nonchagasic individuals, except for a few of
the patients with kala-azar. Patients with other diseases had
positive results for their respective serodiagnoses.
Serum samples were obtained from venous blood and kept
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DIGESTIVE FORMS ( D. F.) ACUTE FORMS (A. F.)
CARDIAC FORMS (C. F) NON- CHAGASIC INDIVIDUALS(NCI)
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FIG. 1. Distribution of IgA antibody titers for epimastigote,
trypomastigote, and amastigote T. cruzi antigens in chagasic and
nonchagasic patients.
Serological tests for Chagas' disease. All sera were assayed
by complement fixation, IF for IgG antibody, and indirect
HA tests for Chagas' disease as described previously (5).
Serum samples from chagasic patients were also tested by an
enzyme-linked immunosorbent assay for IgG antibodies
(23). Also, IF for IgM antibody and polysaccharide HA tests
were performed to detect IgM antibodies in the acute cases
(14). To avoid interference of rheumatoid factors in the IgM
IF test, we pretreated serum samples which were positive in
a rheumatoid factor latex agglutination test (Behringwerke
A.G.) with aggregated human gamma globulin (22). In the IF
tests, an anti-IgA, a-chain-specific conjugate was used. To
ensure the specificity of results with amastigote antigens, we
retested positive sera in the IF test after they were absorbed
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FIG. 2. Frequency, determined by the IF test, of antiamastigote
IgA antibody titers in patients with digestive forms of Chagas'
disease (O) and in patients with other chronic forms of Chagas'
disease, patients with nonrelated pathologies, and healthy individu-
als (0).
Parasite antigens. Parasite antigens were prepared from
various T. cruzi (Y strain) life cycle stages. Epimastigote
antigens were obtained as described previously (4). Blood-
stream trypomastigotes were collected from immunosup-
pressed mice (9) inoculated with 10-5 trypomastigotes 4 h
after injection of the immunosuppressor drug. Blood was
taken on day 7 postinfection, at the peak of parasitemia, by
heart puncture, defibrinated with glass beads, centrifuged at
1,000 x g for 1 min at room temperature, and left for 10 min
at 37°C before removal of the supernatant plasma. This
plasma, rich in parasites, was then centrifuged at 1,000 x g
for 15 min at 4°C. Sedimented trypanosomes were washed
twice in medium 199 (GIBCO Laboratories) with 1% bovine
serum albumin (fraction V; Sigma Chemical Co.). Parasites
were then processed as described for epimastigotes (4).
Intracellular amastigotes were taken from the spleen and
liver of infected mice, purified by two-step discontinuous
gradient centrifugation as described previously (1), and
processed as described for epimastigotes (4).
RESULTS
Serum samples from chagasic patients were all reactive in
the enzyme-linked immunosorbent assay, and most were
reactive in the three other conventional tests, IgG IF, HA,
and complement fixation, or at least in two of these. Samples
from patients with other diseases were nonreactive, except
for five cases of kala-azar. The 28 serum samples from
TABLE 1. IgA IF test results with T. cruzi amastigote, trypomastigote, or epimastigote antigens in individuals with chronic digestive
forms (DF) of Chagas' disease and in nonchagasic individuals (NCI)
SpeCifiCitya ~~~Cutoif titer L0g2 GMT ±4 SD for:Antigen Sensitivitya Specificitya Efficiencya (1og2) DF NCI
Amastigote 0.920 0.911 0.912 10 12.7 + 3.8 5.1 ± 3.0
Trypomastigote 0.200 0.777 0.714 3 1.4 ± 2.0 1.6 ± 1.8
Epimastigote 0.000 0.678 0.604 1 0.0 1.2 ± 1.5
















































IgA ANTIBODIES IN DIGESTIVE FORMS OF CHAGAS' DISEASE
o00f EPIMASTIGOTE TRYPOMASTIGOTE AMASTIGOTE
O50-
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AF IF CF DF NCI AF IF CF DF NCI AF IF CF DF NCI
FIG. 3. Positive IgA IF tests with T. cruzi epimastigote, trypomastigote, or amastigote antigens in individuals with acute (AF),
indeterminate (IF), cardiac (CF), and digestive (DF) forms of Chagas' disease and in nonchagasic individuals (NCI).
patients with acute Chagas' disease were reactive in the IgM
IF and polysaccharide HA tests. The results of the IF for
IgA antibody tests with epimastigotes, trypomastigotes, or
amastigotes are shown in Fig. 1.
Our purpose was to define an immunological marker for
the digestive forms of Chagas' disease. Cutoff titers (Fig. 1)
were established for each test to separate, with the highest
possible efficiency, patients with digestive forms from pa-
tients with all other chronic forms of Chagas' disease, other
infections, and no infections (normal individuals). Patients
with acute forms were not included in either group since,
although they have IgA-reactive antibodies, they can be
distinguished from patients with other forms of Chagas'
disease because they have anti-T. cruzi IgM antibodies in
their sera. Figure 2 depicts the frequency of titers for both
groups in the IgA IF test with amastigotes. The best cutoff
observed between the left curve corresponding to the diges-
tive forms and the right curve corresponding to all other
forms except for acute forms is also shown.
Table 1 indicates sensitivity, specificity, and efficiency
indices for the selected cutoffs. As shown in Fig. 1 and 3,
TABLE 2. Positive IgA IF tests with amastigote, trypomastigote,
or epimastigote antigens in serum samples from chagasic and
nonchagasic patients
No. of No. of positive results with:
Diagnosis serum Amas- Trypomas- Epimas-
samples tigotes tigotes tigotes
Chagas' disease
Acute 28 16 15 5
Chronic
Digestive 25 23 5 0
Cardiac 26 5 0 5
Indeterminate 56 12 7 15
Other diseases
Rubella 10 0 2 0
Toxoplasmosis 10 0 2 1
Malaria 10 0 0 0
Kala-azar 10 0 0 1
Mucocutaneous 10 0 7 0
leishmaniasis
Syphilis 10 0 9 10
Connective tissue 10 0 3 4
diseases
None (normal individuals) 50 1 15 29
antiamastigote IgA antibodies in the digestive forms had a
geometric mean titer (GMT) of 16,635 and titers of 2,560 or
higher in 23 of 25 cases. In contrast, GMTs were 394 and
597, respectively, for the indeterminate and cardiac forms,
both of which were represented by titers of 2,560 or higher in
only 20% of cases. In the group of nonchagasic individuals,
99.2% had negative results and a GMT of 86.
In the IgA IF tests with epimastigotes and trypomasti-
gotes, much lower titers were seen, and no significant
differences were observed among individuals with the dif-
ferent forms of Chagas' disease and nonchagasic individuals.
Table 2 indicates the reactivities seen for serum samples
from patients in the several groups studied in relation to the
established cutoffs.
DISCUSSION
The data presented here show a close positive correlation
between the digestive forms of chronic Chagas' disease and
high titers of antiamastigote IgA antibodies in serum. Titers
between 2,560 and 655,360 were seen in 23 of 25 cases, with
a GMT of 16,635.
In patients with digestive tract involvement, the finding of
IgA antibodies in serum seems to be significant and might
constitute an early signal of active mucosal lesions of, for
example, mucocutaneous leishmaniasis (12, 21) and mycoses
with mucous membrane or respiratory tract implications (3).
However, specific IgA antibodies in serum are not observed
in advanced cases of mucocutaneous leishmaniasis with a
long history of destructive lesions (12). The persistence of
IgA antibodies in the digestive forms of chronic Chagas'
disease is thus an unexpected finding. Although present in
lower titers, antiamastigote IgA antibodies were also ob-
served in significant titers in about 20% of patients with
indeterminate forms. These patients should be closely mon-
itored to verify whether the disease will progress with the
onset of digestive disturbances. For the cardiac form, about
20% of the patients were also positive for antiamastigote IgA
antibodies; a few already had digestive impairment.
Amastigote antigens proved to be much more sensitive for
revealing IgA antibodies than the other T. cruzi antigens.
Amastigotes from T. cruzi-infected mice were not only easier
to obtain but also had a higher reactivity than those from cell
cultures (2). In tests with the former, serum samples were
previously absorbed with mouse liver and kidney powders to
avoid possible interference by animal tissue components.
The presence of IgA antibodies in the acute phase of
Chagas' disease, as observed here, was an expected finding,
since these class-specific antibodies have pathogenic signif-
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icance and diagnostic value in several nonrelated acute
infections (12, 19, 20). The results shown in Table 2 suggest
that IgA antibodies in acute Chagas' disease differ in speci-
ficity from IgA antibodies related to the digestive forms. The
former antibodies reacted in a similar way to both amasti-
gotes and trypomastigotes, while the latter had a much
higher reactivity with amastigotes. Such aspects are now
under investigation with the help of Western blotting (immu-
noblotting) techniques. The high cross-reactivity of IgA
antibodies from patients with syphilis or mucocutaneous
leishmaniasis against trypomastigote and epimastigote anti-
gens might be explained by ubiquitous antigenic determi-
nants common to Treponema pallidum and Leishmania sp.
amastigotes but absent from T. cruzi amastigotes.
Confirmation of the development of digestive impairment
in patients with the indeterminate forms by a positive
antiamastigote IgA test may provide a valuable alternative
and serve as an early aid in the diagnosis of digestive forms
of Chagas' disease, usually limited to radiologic procedures.
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